William R Hiatt

List of Publications by Year
in descending order

104 papers	6,665 citations	101543 36 h-index	62596 80 g-index
104 all docs	104 docs citations	104 times ranked	7419 citing authors

#	Article	IF	Citations
1	Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. Journal of Vascular Surgery, 2022, 75, 660-670.e3.	1.1	2
2	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation, 2022, 145, 1471-1479.	1.6	6
3	Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open, 2022, 06, e177-e183.	1.4	1
4	Plantar Flexionâ€“Induced Entrapment of the Dorsalis Pedis Artery in a Teenaged Cross-Country Runner. Annals of Vascular Surgery, 2021, 70, 213-218.	0.9	1
5	Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. Journal of Medical Economics, 2021, 24, 402-409.	2.1	5
6	Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease. JACC Basic To Translational Science, 2021, 6, 174-188.	4.1	13
7	Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007539.	2.2	33
8	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. International Journal of COPD, 2021, Volume 16, 841-851.	2.3	6
9	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. American Heart Journal, 2021, 235, 12-23.	2.7	36
10	Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vascular Medicine, 2021, 26, 1358863X2110176.	1.5	0
11	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. Journal of the American Heart Association, 2021, 10, e018684.	3.7	13
12	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 77, 3016-3027.	2.8	23
13	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PADÂTrial. Journal of the American College of Cardiology, 2021, 78, 317-326.	2.8	30
14	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circulation: Cardiovascular Interventions, 2021, 14, e009871.	3.9	2
15	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation, 2021, 144, 1104-1116.	1.6	25
16	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75Âyears of age or older. Journal of Thrombosis and Haemostasis, 2021, 19, 2772-2780.	3.8	4
17	Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Annals of Vascular Surgery, 2021, 75, 217-226.	0.9	5
18	World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. Vascular Medicine, 2021, , 1358863X2110386.	1.5	2

#	Article	IF	Citations
19	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral ArteryÂRevascularization. Journal of the American College of Cardiology, 2021, 78, 1768-1778.	2.8	19
20	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2020, 13, e009326.	3.9	7
21	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006512.	2.2	16
22	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 e016573.	3.7	7
23	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation, 2020, 142, 2219-2230.	1.6	58
24	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Thrombosis and Haemostasis, 2020, 120, 866-875.	3.4	52
25	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and MajorÂThromboembolic Events in MedicallyÂIllÂPatients. Journal of the American College of Cardiology, 2020, 75, 3140-3147.	2.8	50
26	From the Masters: A sea-change for TransAtlantic Inter-Society Consensus (TASC). Vascular Medicine, 2020, 25, 103-105.	1.5	3
27	Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine, 2020, 382, 1994-2004.	27.0	566
28	Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back. European Heart Journal, 2020, 41, 1650-1652.	2.2	3
29	Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. Journal of the American College of Cardiology, 2020, 75, 498-508.	2.8	57
30	Inflammatory Cytokines Associated With Failure of Lower-Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes. Diabetes Care, 2019, 42, 1939-1945.	8.6	38
31	Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. Vascular Medicine, 2019, 24, 422-430.	1.5	13
32	Heterogeneity of Risk and Benefit in Subgroups of COMPASS. Journal of the American College of Cardiology, 2019, 73, 3292-3294.	2.8	1
33	Impact of Procedural Bleeding in Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008069.	3.9	6
34	Acute Limb Ischemia in Peripheral Artery Disease. Circulation, 2019, 140, 556-565.	1.6	80
35	Lost in translation: Why â€˜lost to follow-upâ€™ matters. Vascular Medicine, 2019, 24, 339-340.	1.5	4
36	Stroke in Patients With Peripheral Artery Disease. Stroke, 2019, 50, 1356-1363.	2.0	33

#	Article	IF	Citations
37	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. Diabetologia, 2019, 62, 926-938.	6.3	94
38	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. JAMA Cardiology, 2019, 4, 7.	6.1	26
39	Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. Vascular Medicine, 2018, 23, 513-522.	1.5	1
40	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). American Heart Journal, 2018, 199, 83-91.	2.7	104
41	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. European Journal of Vascular and Endovascular Surgery, 2018, 55, 109-117.	1.5	28
42	Cardiovascular and Limb Outcomes in Patients With Diabetes and PeripheralÂArtery Disease. Journal of the American College of Cardiology, 2018, 72, 3274-3284.	2.8	64
43	Guidelineâ€directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clinical Cardiology, 2018, 41, 1414-1422.	1.8	5
44	Cardiovascular Outcomes After LowerÂExtremity Endovascular or SurgicalÂRevascularization. Journal of the American College of Cardiology, 2018, 72, 1563-1572.	2.8	39
45	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	2.7	276
46	Major Adverse Limb Events and 1-YearÂOutcomes After PeripheralÂArteryÂRevascularization. Journal of the American College of Cardiology, 2018, 72, 999-1011.	2.8	76
47	The Treatment Gap in PeripheralÂArteryÂDisease. Journal of the American College of Cardiology, 2017, 69, 2301-2303.	2.8	17
48	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. Circulation, 2017, 135, 2534-2555.	1.6	136
49	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. New England Journal of Medicine, 2017, 376, 32-40.	27.0	494
50	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. Circulation, 2017, 135, 241-250.	1.6	111
51	Response by Hess and Hiatt to Letter Regarding Article, â€œA Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 2524-2525.	1.6	0
52	Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries. International Angiology, 2017, 36, 203-215.	0.9	13
53	Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?. Diabetes Care, 2016, 39, 738-742.	8.6	52
54	The Development of Therapeutics forÂPeripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2729-2731.	2.8	1

#	Article	IF	Citations
55	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. Circulation, 2016, 133, 2459-2502.	1.6	766
56	Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 1338-1357.	2.8	144
57	Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. American Heart Journal, 2016, 175, 86-93.	2.7	41
58	Nonatherosclerotic limb ischemia: Prompt evaluation and diagnosis. Cleveland Clinic Journal of Medicine, 2016, 83, 741-751.	1.3	0
59	An update on methods for revascularization and expansion of the TASC lesion classification to include belowâ€theâ€knee arteries: A supplement to the interâ€society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee*. Catheterization and Cardiovascular Interventions, 2015, 86, 611-625.	1.7	76
60	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Annals of Vascular Diseases, 2015, 8, 343-357.	0.5	122
61	Community-based walking exercise for peripheral artery disease: An exploratory pilot study. Vascular Medicine, 2015, 20, 339-347.	1.5	39
62	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. American Heart Journal, 2015, 170, 490-497.e1.	2.7	26
63	Evaluation and Treatment of Patients With Lower Extremity Peripheral ArteryÂDisease. Journal of the American College of Cardiology, 2015, 65, 931-941.	2.8	269
64	Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease. Circulation Research, 2015, 116, 1527-1539.	4.5	128
65	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. American Heart Journal, 2015, 169, 486-495.	2.7	21
66	Cardiovascular Drug Development. Journal of the American College of Cardiology, 2015, 65, 1567-1582.	2.8	168
67	The Society for Vascular Medicine: The first quarter century. Vascular Medicine, 2015, 20, 60-68.	1.5	5
68	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries. Journal of Endovascular Therapy, 2015, 22, 663-677.	1.5	152
69	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Vascular Medicine, 2015, 20, 465-478.	1.5	127
70	Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. Vascular Medicine, 2014, 19, 473-482.	1.5	39
71	Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. Vascular Medicine, 2014, 19, 297-306.	1.5	8
72	Clinical Trials in Peripheral Vascular Disease. Circulation, 2014, 130, 1812-1819.	1.6	40

#	Article	IF	Citations
73	Rationale and Design for PACE: Patients with Intermittent Claudication Injected with ALDH Bright Cells. American Heart Journal, 2014, 168, 667-673.e2.	2.7	24
74	Heart Failure and Peripheral Artery Disease. JACC: Heart Failure, 2014, 2, 455-456.	4.1	1
75	Assessing the Clinical Benefits of Lipid-Disorder Drugs. New England Journal of Medicine, 2014, 370, 396-399.	27.0	12
76	Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. Journal of Vascular Surgery, 2014, 60, 686-695.e2.	1.1	346
77	The Cardiovascular Safety of Diabetes Drugs â€" Insights from the Rosiglitazone Experience. New England Journal of Medicine, 2013, 369, 1285-1287.	27.0	163
78	Cardiovascular Risk Assessment in the Development of New Drugs for Obesity. JAMA - Journal of the American Medical Association, 2012, 308, 1099.	7.4	13
79	A validated biomarker panel to identify peripheral artery disease. Vascular Medicine, 2012, 17, 386-393.	1.5	14
80	Effect of Propionyl-L-carnitine on a Background of Monitored Exercise in Patients With Claudication Secondary to Peripheral Artery Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2011, 31, 125-132.	2.1	31
81	Response to Letter Regarding Article, â€œAcute Pharmacological Conversion of Atrial Fibrillation to Sinus Rhythmâ€• Circulation, 2009, 119, .	1.6	0
82	The Kids-DOTT Trial: Novel Aspects of the â€˜Parallel Cohort RCTâ€˜ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.. Blood, 2009, 114, 4169-4169.	1.4	4
83	Acute Pharmacological Conversion of Atrial Fibrillation to Sinus Rhythm. Circulation, 2008, 117, 2956-2957.	1.6	12
84	Masterclass series in peripheral arterial disease. Vascular Medicine, 2006, 11, 55-60.	1.5	23
85	New Drug Application 21-628, Certican (Everolimus), for the Proposed Indication of Prophylaxis of Rejection in Heart Transplantation. Circulation, 2006, 113, e394-5.	1.6	13
86	Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials. Vascular Medicine, 2005, 10, 207-213.	1.5	20
87	The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. Vascular Medicine, 2004, 9, 271-277.	1.5	13
88	Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vascular Medicine, 2004, 9, 18-25.	1.5	16
89	Carnitine and Peripheral Arterial Disease. Annals of the New York Academy of Sciences, 2004, 1033, 92-98.	3.8	51
90	Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes. Circulation, 2003, 107, 753-756.	1.6	216

#	Article	IF	Citations
91	Pharmacologic therapy for peripheral arterial disease and claudication. Journal of Vascular Surgery, 2002, 36, 1283-1291.	1.1	73
92	Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs. ACP Journal Club, 2002, 137, 12.	0.1	0
93	Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs. ACP Journal Club, 2002, 137, 12.	0.1	1
94	Review: Magnetic resonance angiography detects lower-extremity arterial disease in claudication or critical limb ischemia. ACP Journal Club, 2001, 135, 109.	0.1	0
95	Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. Journal of Applied Physiology, 1999, 87, 809-816.	2.5	82
96	Propionyl-L-Carnitine. Drugs and Aging, 1998, 12, 0003-0249.	2.7	0
97	Effect of Diagnostic Criteria on the Prevalence of Peripheral Arterial Disease. Circulation, 1995, 91, 1472-1479.	1.6	441
98	Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. Clinical Pharmacology and Therapeutics, 1994, 55, 681-692.	4.7	69
99	Review: Î²-blockers do not reduce walking capacity or calf blood flow in peripheral arterial disease. ACP Journal Club, 1992, 116, 3.	0.1	0
100	Shortâ€Term Effects of Estrogen and Progestin on Blood Pressure of Normotensive Postmenopausal Women. Journal of Clinical Pharmacology, 1991, 31, 543-548.	2.0	21
101	Age does not alter human vascular and nonvascular Î²2-adrenergic responses to isoproterenol. Clinical Pharmacology and Therapeutics, 1988, 44, 573-578.	4.7	28
102	Beta-2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. Clinical Pharmacology and Therapeutics, 1985, 37, 2-6.	4.7	31
103	The Effect of Platelet Protein and Dna on the Measurement of Human Lymphocyte Beta Adrenergic Receptor Number. Journal of Receptors and Signal Transduction, 1985, 5, 419-429.	1.2	1
104	Selective and nonselective Î²-blockade of the peripheral circulation. Clinical Pharmacology and Therapeutics, 1984, 35, 12-18.	4.7	18